PMID- 37167898
OWN - NLM
STAT- MEDLINE
DCOM- 20230619
LR  - 20240104
IS  - 1096-3618 (Electronic)
IS  - 1044-5323 (Linking)
VI  - 68
DP  - 2023 Jul
TI  - Targeting dendritic cells to advance cross-presentation and vaccination outcomes.
PG  - 101762
LID - S1044-5323(23)00053-2 [pii]
LID - 10.1016/j.smim.2023.101762 [doi]
AB  - Dendritic cells (DCs) are a complex network of specialised antigen-presenting 
      cells that are critical initiators of adaptive immunity. Targeting antigen 
      directly to DCs in situ is a vaccination strategy that selectively delivers 
      antigen to receptors expressed by DC subtypes. This approach exploits specific DC 
      subset functions of antigen uptake and presentation. Here, we review DC-targeted 
      vaccination strategies that are designed to elicit effective cross-presentation 
      for CD8(+) T cell immunity. In particular, we focus on approaches that exploit 
      receptors highly expressed by mouse and human cDCs equipped with superior 
      cross-presentation capacity. These receptors include DEC205, Clec9A and XCR1. 
      Targeting DC receptors Clec12A, Clec4A4 and mannose receptor is also reviewed. 
      Outcomes of DC-targeted vaccination in mouse models through to human clinical 
      trials is discussed. This is a promising new vaccination approach capable of 
      directly targeting the cross-presentation pathway for prevention and treatment of 
      tumours and infectious diseases.
CI  - Copyright (c) 2023 Elsevier Ltd. All rights reserved.
FAU - Macri, Christophe
AU  - Macri C
AD  - Department of Biochemistry and Pharmacology, The University of Melbourne, Bio21 
      Molecular Science and Biotechnology Institute, 30 Flemington Rd, Parkville, 
      Victoria 3010, Australia.
FAU - Jenika, Devi
AU  - Jenika D
AD  - Department of Biochemistry and Pharmacology, The University of Melbourne, Bio21 
      Molecular Science and Biotechnology Institute, 30 Flemington Rd, Parkville, 
      Victoria 3010, Australia.
FAU - Ouslinis, Cassandra
AU  - Ouslinis C
AD  - Department of Biochemistry and Pharmacology, The University of Melbourne, Bio21 
      Molecular Science and Biotechnology Institute, 30 Flemington Rd, Parkville, 
      Victoria 3010, Australia.
FAU - Mintern, Justine D
AU  - Mintern JD
AD  - Department of Biochemistry and Pharmacology, The University of Melbourne, Bio21 
      Molecular Science and Biotechnology Institute, 30 Flemington Rd, Parkville, 
      Victoria 3010, Australia. Electronic address: jmintern@unimelb.edu.au.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20230509
PL  - England
TA  - Semin Immunol
JT  - Seminars in immunology
JID - 9009458
RN  - 0 (Antigens)
SB  - IM
MH  - Animals
MH  - Humans
MH  - Mice
MH  - *Cross-Priming
MH  - *Antigen Presentation
MH  - CD8-Positive T-Lymphocytes
MH  - Antigens
MH  - Vaccination
MH  - Dendritic Cells
OTO - NOTNLM
OT  - Antigen presentation
OT  - Cross-presentation
OT  - Dendritic cells
OT  - Vaccination
COIS- Conflict of interest The authors declare no conflict of interest.
EDAT- 2023/05/12 01:07
MHDA- 2023/06/19 13:08
CRDT- 2023/05/11 18:10
PHST- 2022/12/09 00:00 [received]
PHST- 2023/04/06 00:00 [revised]
PHST- 2023/04/06 00:00 [accepted]
PHST- 2023/06/19 13:08 [medline]
PHST- 2023/05/12 01:07 [pubmed]
PHST- 2023/05/11 18:10 [entrez]
AID - S1044-5323(23)00053-2 [pii]
AID - 10.1016/j.smim.2023.101762 [doi]
PST - ppublish
SO  - Semin Immunol. 2023 Jul;68:101762. doi: 10.1016/j.smim.2023.101762. Epub 2023 May 
      9.